prednisolone has been researched along with ANCA-Associated Vasculitides in 60 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We herein report a case of otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV) induced by propylthiouracil (PTU)." | 7.88 | Propylthiouracil-induced Otitis Media with Antineutrophil Cytoplasmic Antibody-associated Vasculitis. ( Kishida, D; Moteki, H; Sekijima, Y; Shimojima, Y; Tanaka, R; Ueno, KI, 2018) |
| "Microscopic polyangiitis is a necrotising vasculitis characterised by anti-neutrophil cytoplasmic antibodies against myeloperoxidase." | 5.91 | Gradual increase of avacopan dose with concomitant ursodeoxycholic acid use may help avoid the risk of C5a receptor inhibitor-induced liver injury in antineutrophil cytoplasmic antibody-associated vasculitis. ( Kataoka, H; Kondo, M; Mukai, M; Nakanowatari, M; Tomita, T, 2023) |
| "Hydralazine-induced lupus was first described in 1953." | 5.48 | Hydralazine-associated antineutrophil cytoplasmic antibody vasculitis with pulmonary-renal syndrome. ( Aeddula, NR; Ansari, A; Juran, PJ; Pathireddy, S, 2018) |
| " We finally diagnosed recurrent granulomatosis with polyangiitis and initiated methyl-prednisolone pulse therapy (1,000 mg) followed by prednisolone (30 mg/day) and rituximab (RTX)." | 3.88 | Rituximab-induced Acute Thrombocytopenia in Granulomatosis with Polyangiitis. ( Endo, Y; Fujita, Y; Fukui, S; Ichinose, K; Igawa, T; Ishida, M; Iwamoto, N; Kawakami, A; Kawashiri, SY; Koga, T; Nakamura, H; Nishino, A; Origuchi, T; Shimizu, T; Sumiyoshi, R; Takatani, A; Tamai, M; Tsuji, S; Umeda, M, 2018) |
| "We herein report a case of otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV) induced by propylthiouracil (PTU)." | 3.88 | Propylthiouracil-induced Otitis Media with Antineutrophil Cytoplasmic Antibody-associated Vasculitis. ( Kishida, D; Moteki, H; Sekijima, Y; Shimojima, Y; Tanaka, R; Ueno, KI, 2018) |
| " A phase II selection design will be used to determine hdroxychloroquine's efficacy, using prednisolone dosage and Birmingham Vasculitis Activity Score as a measure of disease activity." | 3.30 | The HAVEN study-hydroxychloroquine in ANCA vasculitis evaluation-a multicentre, randomised, double-blind, placebo-controlled trial: study protocol and statistical analysis plan. ( Arnold, L; Beckley-Hoelscher, N; Cape, A; Casian, A; D'Cruz, D; Douiri, A; Galloway, J; Jayne, D; John, S; Kim, S; Learoyd, AE; Luqmani, R; Morton, N; Nel, L; Reid, F; Sangle, S; Shivapatham, D, 2023) |
| " The lack of a robust evidence base to guide the use of plasma exchange and glucocorticoid dosing contributes to variation in practice and suboptimal outcomes." | 3.11 | Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT. ( Brettell, EA; Brezina, B; Broadhurst, E; Casian, A; Clark, W; de Zoysa, J; Flossmann, O; Fujimoto, S; Girard, L; Gregorini, G; Harper, L; Hawley, C; Ito-Ihara, T; Ives, N; Jarrett, H; Jayne, D; Jones, R; Khalidi, N; Levin, A; Mazzetti, A; McAlear, CA; Mehta, S; Merkel, PA; Pagnoux, C; Peh, CA; Puéchal, X; Pusey, CD; Reidlinger, D; Smyth, L; Specks, U; Szpirt, W; Wald, R; Walsh, M; Wheatley, K, 2022) |
| "Diagnosis of Wegener's granulomatosis was made from the findings of a nodular lesion in the left lung." | 2.46 | Refractory antineutrophil cytoplasmic antibody-associated vasculitis successfully treated with rituximab: a case report. ( Ando, H; Hirata, A; Horai, Y; Minami, R; Miyamura, T; Nakamura, M; Suematsu, E; Takahama, S; Yamamoto, M, 2010) |
| "We reported a rare case of comorbid systemic sclerosis and antineutrophil cytoplasmic antibody-associated vasculitis with nasal perforation." | 1.91 | Glomerulonephritis associated with systemic sclerosis: a case report. ( Atef-Yekta, R; Kavosi, H; Nayebirad, S; Nili, F; Ramandi, A; Salehi, S; Tamartash, Z, 2023) |
| "Microscopic polyangiitis is a necrotising vasculitis characterised by anti-neutrophil cytoplasmic antibodies against myeloperoxidase." | 1.91 | Gradual increase of avacopan dose with concomitant ursodeoxycholic acid use may help avoid the risk of C5a receptor inhibitor-induced liver injury in antineutrophil cytoplasmic antibody-associated vasculitis. ( Kataoka, H; Kondo, M; Mukai, M; Nakanowatari, M; Tomita, T, 2023) |
| "She then developed bronchial asthma and mild eosinophilia (eosinophilic count: ~1000/μL)." | 1.72 | Development of eosinophilic granulomatosis with polyangiitis during the clinical course of microscopic polyangiitis: A case report. ( Abe, K; Ichinose, K; Ide, H; Kawakami, A; Koike, Y; Kojima, K; Nishihata, S; Shigematsu, K; Shimizu, T, 2022) |
| "Age, frailty score and CRP at presentation were independently associated with mortality; all deaths occurred in patients aged over 75 at presentation." | 1.56 | Long-term outcomes in elderly patients with ANCA-associated vasculitis. ( Dhaun, N; Farrah, TE; Gallacher, PJ; Hunter, RW; Kluth, DC; McGovern, D; Miller-Hodges, E; Parsons, K; Williams, SP, 2020) |
| "Hydralazine-induced lupus was first described in 1953." | 1.48 | Hydralazine-associated antineutrophil cytoplasmic antibody vasculitis with pulmonary-renal syndrome. ( Aeddula, NR; Ansari, A; Juran, PJ; Pathireddy, S, 2018) |
| " For initial remission induction, RTX was dosed at 1 g every 2 weeks or 375 mg/m(2) weekly for 4 consecutive weeks and for remission maintenance at 1 g every 6 months for 24 months." | 1.42 | Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. ( Alberici, F; Chaudhry, A; Jayne, DR; Jones, RB; Roberts, DM; Smith, KG; Smith, RM; Willcocks, LC, 2015) |
| "Prednisolone doses were negatively linked to SPIB and miR-155-5p, miR-339-5p (PBMC) and to miR-221, miR-361 and miR-505 (PMN)." | 1.40 | A myelopoiesis gene signature during remission in anti-neutrophil cytoplasm antibody-associated vasculitis does not predict relapses but seems to reflect ongoing prednisolone therapy. ( Basnet, S; Eriksson, P; Kurz, T; Segelmark, M; Skoglund, C; Weiner, M, 2014) |
| "Rituximab is effective in inducing remission in ANCA-associated vasculitis (AAV), with randomized evidence to support its use as four infusions of 375 mg/m(2) (the conventional lymphoma dosing schedule)." | 1.40 | Induction treatment of ANCA-associated vasculitis with a single dose of rituximab. ( Ashley, C; Burns, A; Dinneen, D; Howie, AJ; Little, MA; Pepper, RJ; Salama, AD; Sandhu, E; Stolagiewicz, NE; Turner-Stokes, T, 2014) |
| "Granulomatosis with polyangiitis is characterized by the involvement of the respiratory tract and kidneys." | 1.40 | A rare association between Fabry's disease and granulomatosis with polyangiitis: a potential pathogenic link. ( Hanaoka, H; Hashiguchi, A; Ishii, T; Konishi, K; Kuwana, M, 2014) |
| "Rituximab-induced pneumonitis was diagnosed on a combination of computed tomography imaging, bronchoalveolar lavage, and negative tests for active vasculitis and infection." | 1.38 | Rituximab associated pneumonitis in antineutrophil cytoplasmic antibody-associated vasculitis. ( Arulkumaran, N; Cecconi, M; Chua, F; Kiely, P; Suleman, R, 2012) |
| "We experienced a rare case of membranous glomerulopathy(MN) with myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-associated glomerulonephritis." | 1.37 | [Case of MPO-ANCA-associated vasculitis with membranous nephropathy]. ( Arimura, Y; Kaname, S; Kawashima, S; Nomura, K; Watanabe, S; Yamada, A; Yoshihara, K, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 42 (70.00) | 24.3611 |
| 2020's | 18 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yashiro-Furuya, M | 1 |
| Sato, S | 3 |
| Akanuma, M | 1 |
| Sato, K | 1 |
| Suzuki, E | 1 |
| Kanno, T | 1 |
| Matsumoto, H | 1 |
| Temmoku, J | 1 |
| Fujita, Y | 2 |
| Matsuoka, N | 1 |
| Asano, T | 1 |
| Kobayashi, H | 1 |
| Watanabe, H | 2 |
| Migita, K | 1 |
| Leong, A | 1 |
| Fong, W | 1 |
| Jayne, D | 5 |
| Walsh, M | 1 |
| Merkel, PA | 1 |
| Peh, CA | 1 |
| Szpirt, W | 1 |
| Puéchal, X | 2 |
| Fujimoto, S | 3 |
| Hawley, C | 1 |
| Khalidi, N | 1 |
| Jones, R | 1 |
| Flossmann, O | 1 |
| Wald, R | 1 |
| Girard, L | 1 |
| Levin, A | 1 |
| Gregorini, G | 1 |
| Harper, L | 1 |
| Clark, W | 1 |
| Pagnoux, C | 2 |
| Specks, U | 1 |
| Smyth, L | 1 |
| Ito-Ihara, T | 1 |
| de Zoysa, J | 1 |
| Brezina, B | 1 |
| Mazzetti, A | 1 |
| McAlear, CA | 1 |
| Reidlinger, D | 1 |
| Mehta, S | 1 |
| Ives, N | 1 |
| Brettell, EA | 1 |
| Jarrett, H | 1 |
| Wheatley, K | 1 |
| Broadhurst, E | 1 |
| Casian, A | 2 |
| Pusey, CD | 1 |
| Suzuki, M | 1 |
| Sekiguchi, Y | 1 |
| Sasaki, M | 1 |
| Inaba, S | 1 |
| Oyama, S | 1 |
| Inoue, Y | 1 |
| Warabi, M | 1 |
| Ohashi, K | 1 |
| Inoshita, S | 1 |
| Ide, H | 1 |
| Shimizu, T | 2 |
| Koike, Y | 1 |
| Abe, K | 1 |
| Shigematsu, K | 1 |
| Nishihata, S | 1 |
| Kojima, K | 1 |
| Ichinose, K | 3 |
| Kawakami, A | 4 |
| Nayebirad, S | 1 |
| Ramandi, A | 1 |
| Nili, F | 1 |
| Atef-Yekta, R | 1 |
| Tamartash, Z | 1 |
| Salehi, S | 1 |
| Kavosi, H | 1 |
| Mimura, N | 1 |
| Iwamoto, T | 1 |
| Furuta, S | 2 |
| Ikeda, K | 2 |
| Kobayashi, Y | 1 |
| Nakamura, T | 1 |
| Saku, A | 1 |
| Kagami, SI | 1 |
| Matsuki, A | 1 |
| Takahashi, K | 1 |
| Umibe, T | 2 |
| Nakagomi, D | 2 |
| Sanayama, Y | 1 |
| Sugimoto, T | 1 |
| Fukuta, M | 1 |
| Hiraguri, M | 2 |
| Kawashima, H | 1 |
| Hirose, K | 1 |
| Takatori, H | 1 |
| Suehiro, K | 1 |
| Takahashi, S | 2 |
| Tamachi, T | 1 |
| Kato, M | 1 |
| Takizawa, F | 1 |
| Kawarai, Y | 1 |
| Hagiwara, S | 1 |
| Nakamura, J | 1 |
| Ohtori, S | 1 |
| Nakajima, H | 2 |
| Kataoka, H | 1 |
| Tomita, T | 1 |
| Nakanowatari, M | 1 |
| Kondo, M | 1 |
| Mukai, M | 1 |
| Learoyd, AE | 1 |
| Arnold, L | 1 |
| Reid, F | 1 |
| Beckley-Hoelscher, N | 1 |
| Sangle, S | 1 |
| Morton, N | 1 |
| Nel, L | 1 |
| Cape, A | 1 |
| John, S | 1 |
| Kim, S | 1 |
| Shivapatham, D | 1 |
| Luqmani, R | 1 |
| Galloway, J | 1 |
| Douiri, A | 1 |
| D'Cruz, D | 1 |
| Ikeda, Y | 2 |
| Fukunari, K | 1 |
| Uchiumi, S | 1 |
| Awanami, Y | 1 |
| Kanaya, A | 1 |
| Matsumoto, K | 1 |
| Fukuda, M | 1 |
| Takashima, T | 1 |
| Miyazono, M | 1 |
| McGovern, D | 1 |
| Williams, SP | 1 |
| Parsons, K | 1 |
| Farrah, TE | 1 |
| Gallacher, PJ | 1 |
| Miller-Hodges, E | 1 |
| Kluth, DC | 1 |
| Hunter, RW | 1 |
| Dhaun, N | 1 |
| Sada, KE | 3 |
| Matsumoto, Y | 1 |
| Harigai, M | 2 |
| Amano, K | 4 |
| Dobashi, H | 2 |
| Yuzawa, Y | 1 |
| Yamagata, K | 3 |
| Muso, E | 5 |
| Arimura, Y | 5 |
| Makino, H | 5 |
| Nagiah, S | 1 |
| Saranapala, DMM | 1 |
| Huang, L | 1 |
| Shen, C | 1 |
| Zhong, Y | 1 |
| Ooi, JD | 1 |
| Zhou, YO | 1 |
| Chen, JB | 1 |
| Wu, T | 1 |
| Meng, T | 1 |
| Xiao, Z | 1 |
| Lin, W | 1 |
| Ao, X | 1 |
| Xiao, X | 1 |
| Zhou, Q | 1 |
| Xiao, P | 1 |
| Rao, N | 1 |
| Bendall, A | 1 |
| Lanteri, M | 1 |
| Takagi, M | 1 |
| Kobayashi, T | 1 |
| Kida, T | 1 |
| Takai, N | 1 |
| Shoda, H | 1 |
| Maruyama, K | 1 |
| Tada, R | 1 |
| Makino, S | 1 |
| Ikeda, T | 1 |
| Suchanek, O | 1 |
| Jayne, DRW | 2 |
| Jones, RB | 3 |
| Gopaluni, S | 1 |
| Egan, AC | 1 |
| Xipell, M | 1 |
| Kettritz, R | 1 |
| Karras, A | 1 |
| Haubitz, M | 1 |
| Groot, K | 1 |
| Tervaert, JWC | 1 |
| Segelmark, M | 2 |
| Guillevin, L | 1 |
| Sugiyama, T | 1 |
| Kaneko, Y | 1 |
| Kurasawa, K | 1 |
| Hanaoka, H | 2 |
| Sato, Y | 2 |
| Lin, M | 1 |
| Anesi, SD | 1 |
| Ma, L | 1 |
| Ahmed, A | 1 |
| Small, K | 1 |
| Foster, CS | 1 |
| Ojima, Y | 1 |
| Sawada, K | 1 |
| Fujii, H | 1 |
| Shirai, T | 1 |
| Saito, A | 1 |
| Kagaya, S | 1 |
| Aoki, S | 1 |
| Takeuchi, Y | 1 |
| Ishii, T | 3 |
| Nagasawa, T | 1 |
| Hara, A | 1 |
| Wada, T | 2 |
| Takasaki, Y | 1 |
| Yamada, H | 2 |
| Hasegawa, H | 1 |
| Hayashi, T | 3 |
| Kawakami, T | 1 |
| Homma, S | 1 |
| Yoshida, M | 2 |
| Hirahashi, J | 1 |
| Ogawa, N | 1 |
| Ito, S | 3 |
| Endo, Y | 1 |
| Koga, T | 2 |
| Ishida, M | 1 |
| Tsuji, S | 1 |
| Takatani, A | 1 |
| Sumiyoshi, R | 1 |
| Igawa, T | 1 |
| Umeda, M | 2 |
| Fukui, S | 2 |
| Nishino, A | 2 |
| Kawashiri, SY | 2 |
| Iwamoto, N | 2 |
| Tamai, M | 2 |
| Nakamura, H | 2 |
| Origuchi, T | 2 |
| Tanaka, R | 1 |
| Shimojima, Y | 1 |
| Moteki, H | 1 |
| Kishida, D | 1 |
| Ueno, KI | 1 |
| Sekijima, Y | 1 |
| Snipaitiene, A | 1 |
| Sileikiene, R | 1 |
| Klimaite, J | 1 |
| Jasinskiene, E | 1 |
| Uktveris, R | 1 |
| Jankauskaite, L | 1 |
| Aeddula, NR | 1 |
| Pathireddy, S | 1 |
| Ansari, A | 1 |
| Juran, PJ | 1 |
| Hessels, AC | 2 |
| Tuin, J | 2 |
| Sanders, JSF | 2 |
| Huitema, MG | 1 |
| van Rossum, EFC | 1 |
| Koper, JW | 1 |
| van Beek, AP | 2 |
| Stegeman, CA | 4 |
| Rutgers, A | 3 |
| Di Stefano, V | 1 |
| Dono, F | 1 |
| De Angelis, MV | 1 |
| Onofrj, M | 1 |
| van der Hoeven, JH | 1 |
| Brouwer, E | 1 |
| Fukuhara, A | 1 |
| Tanino, Y | 1 |
| Nikaido, T | 1 |
| Kanazawa, K | 1 |
| Saito, J | 1 |
| Ishida, T | 1 |
| Kanno, M | 1 |
| Watanabe, T | 1 |
| Munakata, M | 1 |
| Kurz, T | 1 |
| Weiner, M | 1 |
| Skoglund, C | 1 |
| Basnet, S | 1 |
| Eriksson, P | 1 |
| Takenaka, K | 1 |
| Ohba, T | 1 |
| Suhara, K | 1 |
| Nagasaka, K | 1 |
| Turner-Stokes, T | 1 |
| Sandhu, E | 1 |
| Pepper, RJ | 1 |
| Stolagiewicz, NE | 1 |
| Ashley, C | 1 |
| Dinneen, D | 1 |
| Howie, AJ | 1 |
| Salama, AD | 1 |
| Burns, A | 1 |
| Little, MA | 1 |
| Lepse, N | 1 |
| Abdulahad, WH | 1 |
| Kallenberg, CG | 1 |
| Heeringa, P | 1 |
| Wakisaka, K | 1 |
| Hagiwara, N | 1 |
| Kanazawa, Y | 1 |
| Arakawa, S | 1 |
| Ago, T | 1 |
| Kitazono, T | 1 |
| Hashiguchi, A | 1 |
| Konishi, K | 1 |
| Kuwana, M | 1 |
| Oiwa, H | 1 |
| Yamasaki, S | 1 |
| Endo, K | 1 |
| Nojima, T | 1 |
| Kumagai, K | 1 |
| Sugiyama, E | 1 |
| Alberici, F | 1 |
| Smith, RM | 2 |
| Roberts, DM | 1 |
| Willcocks, LC | 1 |
| Chaudhry, A | 3 |
| Smith, KG | 2 |
| Jayne, DR | 2 |
| Tsuda, M | 1 |
| Nakashima, Y | 2 |
| Ikeda, M | 1 |
| Shimada, S | 1 |
| Nomura, M | 1 |
| Matsushima, T | 1 |
| Aishima, S | 1 |
| Oda, Y | 1 |
| Shiratsuchi, M | 1 |
| Takayanagi, R | 1 |
| Sasaki, H | 1 |
| Yamazaki, H | 1 |
| Kohsaka, H | 1 |
| Glanville, JR | 1 |
| Penn, H | 1 |
| Sanders, JS | 1 |
| Hoek, A | 1 |
| Hirayama, T | 1 |
| Takazono, T | 1 |
| Horai, Y | 2 |
| Tashiro, M | 1 |
| Saijo, T | 1 |
| Kosai, K | 1 |
| Morinaga, Y | 1 |
| Kurihara, S | 1 |
| Nakamura, S | 1 |
| Imamura, Y | 1 |
| Miyazaki, T | 1 |
| Tsukamoto, M | 1 |
| Izumikawa, K | 1 |
| Yanagihara, K | 1 |
| Kohno, S | 1 |
| Hirai, Y | 1 |
| Fujita, S | 1 |
| Hirayama, K | 2 |
| Ogawa, Y | 1 |
| Shimohata, H | 1 |
| Kobayashi, M | 2 |
| Watts, RA | 1 |
| Laurino, S | 2 |
| Booth, A | 1 |
| Conte, G | 1 |
| Miyamura, T | 1 |
| Takahama, S | 1 |
| Hirata, A | 1 |
| Nakamura, M | 1 |
| Ando, H | 1 |
| Minami, R | 1 |
| Yamamoto, M | 1 |
| Suematsu, E | 1 |
| Watanabe, S | 1 |
| Nomura, K | 1 |
| Kawashima, S | 1 |
| Yoshihara, K | 1 |
| Kaname, S | 1 |
| Yamada, A | 1 |
| Ozaki, S | 2 |
| Atsumi, T | 1 |
| Ishizu, A | 1 |
| Kobayashi, S | 2 |
| Kumagai, S | 1 |
| Kurihara, Y | 1 |
| Kurokawa, MS | 1 |
| Nagafuchi, H | 1 |
| Nakabayashi, K | 1 |
| Nishimoto, N | 1 |
| Suka, M | 2 |
| Tomino, Y | 1 |
| Yumura, W | 2 |
| Hatta, K | 1 |
| Kikuchi, H | 1 |
| Nakashima, H | 1 |
| Ohsone, Y | 1 |
| Suzuki, Y | 1 |
| Hashimoto, H | 1 |
| Koyama, A | 2 |
| Matsuo, S | 2 |
| Kato, H | 1 |
| Arulkumaran, N | 1 |
| Suleman, R | 1 |
| Cecconi, M | 1 |
| Kiely, P | 1 |
| Chua, F | 1 |
| Usui, J | 1 |
| Saito, C | 1 |
| Yamaguchi, N | 1 |
| Mase, K | 1 |
| Sugiyama, H | 1 |
| Nitta, K | 1 |
| Murakami, M | 1 |
| Shimane, K | 1 |
| Takahashi, H | 1 |
| Tomiyama, J | 1 |
| Nagashima, M | 1 |
| Guerry, MJ | 1 |
| Catapano, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis: an International Randomized Controlled Trial[NCT00987389] | Phase 3 | 704 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| Low-dose Glucocorticoids Plus Rituximab Versus High-dose Glucocorticoids Plus Rituximab for Remission Induction in ANCA-associated Vasculitis; a Multicentre, Open Label, Randomised Control Trial[NCT02198248] | Phase 4 | 140 participants (Actual) | Interventional | 2014-10-31 | Active, not recruiting | ||
| TransplantLines: the Transplantation Biobank[NCT03272841] | 3,000 participants (Anticipated) | Observational [Patient Registry] | 2015-06-30 | Active, not recruiting | |||
| ACtive Care After Transplantation, a Lifestyle Intervention in Renal Transplant Recipients[NCT01047410] | 221 participants (Actual) | Interventional | 2010-10-31 | Completed | |||
| Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing Based on B-cell Reconstitution vs a Serologic ANCA Flare[NCT02749292] | Phase 4 | 115 participants (Actual) | Interventional | 2016-06-30 | Terminated (stopped due to Due to the coronavirus disease 2019 (COVID-19) pandemic and the deleterious impact of rituximab on vaccination efficacy, the trial was concluded before reaching the target enrollment of 200.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary outcome was a composite of death from any cause or end-stage renal disease (ESRD), defined as ≥12 continuous weeks of renal replacement therapy. (NCT00987389)
Timeframe: Time frame varied by subject: minimum of 1 year - maximum of 7 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Plasma Exchange | 100 |
| No Plasma Exchange | 109 |
EuroQoL-5 Dimensions consist of 2 elements: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D descriptive system comprised of following 5 dimensions: 1.Mobility, 2.Self-Care, 3.Usual Activities, 4.Pain/Discomfort and 5.Anxiety/Depression. Each of these 5 dimensions has 5 levels: 1: no problems; 2: slight problems; 3: moderate problems; 4: severe problems; 5: Unable to do. The digits for each of 5 dimensions were combined in a 5-digit number describing the participant's health state: e.g. state 11111 indicates no problem on any of the 5 dimensions. Health state index scores generally range from less than 0 (where 0 is a health state equivalent to death; negative values are valued as worse than death) to 1 (perfect health), with higher scores indicating higher health utility. (NCT00987389)
Timeframe: 12 months
| Intervention | score on a scale (Mean) |
|---|---|
| Plasma Exchange | 0.79 |
| No Plasma Exchange | 0.77 |
Quality of life was measured using the 36-item Short Form (SF-36) mental composite scores. Scores for the scale range from 0-100 and transformed to have a mean of 50 and SD of 10 in the reference population, with higher scores indicating a better Health-related Quality of Life. (NCT00987389)
Timeframe: 12 months
| Intervention | score on a scale (Mean) |
|---|---|
| Plasma Exchange | 51.94 |
| No Plasma Exchange | 51.40 |
Quality of life was measured using the 36-item Short Form (SF-36) physical composite scores. Scores for the scale range from 0-100 and transformed to have a mean of 50 and SD of 10 in the reference population, with higher scores indicating a better Health-related Quality of Life. (NCT00987389)
Timeframe: 12 months
| Intervention | units on a scale (Mean) |
|---|---|
| Plasma Exchange | 39.04 |
| No Plasma Exchange | 37.96 |
Remission that occurs before 6 months, and lasts without a first relapse until at least 12 months after randomization (NCT00987389)
Timeframe: Time frame varied by subject: minimum of 1 year - maximum of 7 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Plasma Exchange | 200 |
| No Plasma Exchange | 197 |
Serious infections defined as an infectious syndrome that requires intravenous antibiotics or hospitalization for treatment. (NCT00987389)
Timeframe: Time frame varied by subject: minimum of 1 year - maximum of 7 years
| Intervention | events (Number) |
|---|---|
| Plasma Exchange | 145 |
| No Plasma Exchange | 132 |
Number of disease relapse added with the number of SAE in each group (NCT02749292)
Timeframe: Median follow-up period of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | Number of events (Number) |
|---|---|
| B Cell Reconstitution | 27 |
| Serologic ANCA Flare | 36 |
The rituximab utilization was measured in how many times a subject received Rituximab throughout the study which was then averaged for all subjects in each treatment arm, including those who did not receive any infusion. (NCT02749292)
Timeframe: Median follow-up period of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | Infusions per subject (Mean) |
|---|---|
| B Cell Reconstitution | 3.6 |
| Serologic ANCA Flare | 0.5 |
The Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG ) is a form with 34 predefined items grouped into 9 organ systems. The items are clinical features observed in patients with active ANCA vasculitis. Each item has a specified weight of either 3 or 1, depending on whether it reflects major or minor disease activity. The total BVAS/WG score is the weighted sum of individual manifestations that are present and believed to be due to active ANCA vasculitis. Higher scores reflect more active disease. BVAS/WG scores range from 0 to 64. (NCT02749292)
Timeframe: Median follow-up period of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | number of events (Number) |
|---|---|
| B Cell Reconstitution | 4 |
| Serologic ANCA Flare | 7 |
Number of patients with serious adverse events (SAEs), including all episodes of late onset neutropenia (LON). SAE are defined in the Serious adverse event section. Serious adverse events were reported over the entire study period (5.5 years) (NCT02749292)
Timeframe: Median follow-up period of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | Participants (Count of Participants) |
|---|---|
| B Cell Reconstitution | 15 |
| Serologic ANCA Flare | 14 |
Hypogammaglobulinemia defined as an IgG < 250mg/dL (NCT02749292)
Timeframe: Median follow-up period of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | Participants (Count of Participants) |
|---|---|
| B Cell Reconstitution | 1 |
| Serologic ANCA Flare | 0 |
number of deaths throughout the study. (NCT02749292)
Timeframe: 5.5 years
| Intervention | number of deaths (Number) |
|---|---|
| B Cell Reconstitution | 2 |
| Serologic ANCA Flare | 0 |
The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 is a measure of health status and is commonly used in health economics as a variable in the quality-adjusted life year calculation to determine the cost-effectiveness of a health treatment. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. (NCT02749292)
Timeframe: Assessed throughout the study period, every 6 months unless such time point was not reached or was missed by the patient. Median follow-up period is of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | score on a scale (Mean) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Physical functioning at 6 months | Role functioning/physical at 6 months | Role functioning/emotional at 6 months | Energy/fatigue at 6 months | Emotional well-being at 6 months | Social functioning at 6 months | Pain at 6 months | General health at 6 months | Physical functioning at 36 months | Role functioning/physical at 36 months | Role functioning/emotional at 36 months | Energy/fatigue at 36 months | Emotional well-being at 36 months | Social functioning at 36 months | Pain at 36 months | General health at 36 months | Physical functioning at 12 months | Role functioning/physical at 12 months | Role functioning/emotional at 12 months | Energy/ fatigue at 12 months | Emotional well-being at 12 months | Social functioning at 12 months | Pain at 12 months | General health at 12 months | Physical functioning at 18 months | Role functioning/physical at 18 months | Role functioning/emotional at 18 months | Energy/fatigue at 18 months | Emotional well-being at 18 months | Social functioning at 18 months | Pain at 18 months | General health at 18 months | Physical functioning at 24 months | Role functioning/physical at 24 months | Role functioning/emotional at 24 months | Energy/fatigue at 24 months | Emotional well-being at 24 months | Social functioning at 24 months | Pain at 24 months | General health at 24 months | Physical functioning at 30 months | Role functioning/physical at 30 months | Role functioning/emotional at 30 months | Energy/fatigue at 30 months | Emotional well-being at 30 months | Social functioning at 30 months | Pain at 30 months | General health at 30 months | Physical functioning at 42 months | Role functioning/physical at 42 months | Role functioning/emotional at 42 months | Energy/fatigue at 42 months | Emotional well-being at 42 months | Social functioning at 42 months | Pain at 42 months | General health at 42 months | Physical functioning at 48 months | Role functioning/physical at 48 months | Role functioning/emotional at 48 months | Energy/fatigue at 48 months | Emotional well-being at 48 months | Social functioning at 48 months | Pain at 48 months | General health at 48 months | Physical functioning at 60 months | Role functioning/physical at 60 months | Role functioning/emotional at 60 months | Energy/fatigue at 60 months | Emotional well-being at 60 months | Social functioning at 60 months | Pain at 60 months | General health at 60 months | |
| Serologic ANCA Flare | 82 | 65 | 75 | 67 | 81 | 88 | 82 | 63 | 88 | 79 | 82 | 73 | 84 | 95 | 87 | 70 | 82 | 63 | 68 | 65 | 81 | 86 | 80 | 63 | 82 | 62 | 74 | 68 | 81 | 92 | 82 | 67 | 88 | 71 | 80 | 76 | 85 | 94 | 82 | 70 | 88 | 72 | 80 | 72 | 84 | 94 | 83 | 70 | 82 | 60 | 76 | 70 | 85 | 87 | 82 | 63 | 95 | 100 | 100 | 75 | 85 | 100 | 80 | 75 | 92 | 100 | 89 | 71 | 83 | 92 | 83 | 70 |
The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 is a measure of health status and is commonly used in health economics as a variable in the quality-adjusted life year calculation to determine the cost-effectiveness of a health treatment. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. (NCT02749292)
Timeframe: Assessed throughout the study period, every 6 months unless such time point was not reached or was missed by the patient. Median follow-up period is of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | score on a scale (Mean) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Physical functioning at 6 months | Role functioning/physical at 6 months | Role functioning/emotional at 6 months | Energy/fatigue at 6 months | Emotional well-being at 6 months | Social functioning at 6 months | Pain at 6 months | General health at 6 months | Physical functioning at 36 months | Role functioning/physical at 36 months | Role functioning/emotional at 36 months | Energy/fatigue at 36 months | Emotional well-being at 36 months | Social functioning at 36 months | Pain at 36 months | General health at 36 months | Physical functioning at 12 months | Role functioning/physical at 12 months | Role functioning/emotional at 12 months | Energy/ fatigue at 12 months | Emotional well-being at 12 months | Social functioning at 12 months | Pain at 12 months | General health at 12 months | Physical functioning at 18 months | Role functioning/physical at 18 months | Role functioning/emotional at 18 months | Energy/fatigue at 18 months | Emotional well-being at 18 months | Social functioning at 18 months | Pain at 18 months | General health at 18 months | Physical functioning at 24 months | Role functioning/physical at 24 months | Role functioning/emotional at 24 months | Energy/fatigue at 24 months | Emotional well-being at 24 months | Social functioning at 24 months | Pain at 24 months | General health at 24 months | Physical functioning at 30 months | Role functioning/physical at 30 months | Role functioning/emotional at 30 months | Energy/fatigue at 30 months | Emotional well-being at 30 months | Social functioning at 30 months | Pain at 30 months | General health at 30 months | Physical functioning at 42 months | Role functioning/physical at 42 months | Role functioning/emotional at 42 months | Energy/fatigue at 42 months | Emotional well-being at 42 months | Social functioning at 42 months | Pain at 42 months | General health at 42 months | Physical functioning at 48 months | Role functioning/physical at 48 months | Role functioning/emotional at 48 months | Energy/fatigue at 48 months | Emotional well-being at 48 months | Social functioning at 48 months | Pain at 48 months | General health at 48 months | Physical functioning at 54 months | Role functioning/physical at 54 months | Role functioning/emotional at 54 months | Energy/fatigue at 54 months | Emotional well-being at 54 months | Social functioning at 54 months | Pain at 54 months | General health at 54 months | Physical functioning at 60 months | Role functioning/physical at 60 months | Role functioning/emotional at 60 months | Energy/fatigue at 60 months | Emotional well-being at 60 months | Social functioning at 60 months | Pain at 60 months | General health at 60 months | |
| B Cell Reconstitution | 84 | 66 | 79 | 65 | 83 | 89 | 79 | 66 | 74 | 50 | 65 | 58 | 76 | 83 | 69 | 60 | 79 | 61 | 82 | 65 | 86 | 92 | 81 | 66 | 83 | 70 | 88 | 69 | 85 | 96 | 84 | 68 | 83 | 71 | 84 | 68 | 82 | 91 | 81 | 69 | 85 | 74 | 87 | 64 | 81 | 90 | 86 | 60 | 76 | 58 | 67 | 60 | 77 | 85 | 83 | 59 | 65 | 67 | 67 | 52 | 73 | 65 | 70 | 61 | 88 | 50 | 67 | 67 | 84 | 84 | 81 | 59 | 72 | 33 | 100 | 48 | 82 | 63 | 53 | 58 |
Number of infections mild and severe, whether they were treated or not with antibiotics (NCT02749292)
Timeframe: Median follow-up period of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | number of events (Number) | |
|---|---|---|
| Serious Adverse Events- Infections | Adverse Events- Infections | |
| B Cell Reconstitution | 12 | 72 |
| Serologic ANCA Flare | 6 | 59 |
Relapses recording period was from 6/1/2016 to 12/31/2021. The outcome was reported as the number of participants with disease relapse who had either positive ANCA titers specific for myeloperoxidase (MPO-ANCA) or proteinase 3 (PR3-ANCA). The Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG ) is a form with 34 predefined items grouped into 9 organ systems. The items are clinical features observed in patients with active ANCA vasculitis. Each item has a specified weight of either 3 or 1, depending on whether it reflects major or minor disease activity. The total BVAS/WG score is the weighted sum of individual manifestations that are present and believed to be due to active ANCA vasculitis. Higher scores reflect more active disease. BVAS/WG scores range from 0 to 64. (NCT02749292)
Timeframe: Median follow-up period of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| PR3 | MPO | |
| B Cell Reconstitution | 1 | 4 |
| Serologic ANCA Flare | 7 | 7 |
The Vasculitis Damage Index (VDI) is a validated formal assessment tool in ANCA-associated vasculitis clinical trials. The VDI distinguishes vasculitis-induced chronic damage from active inflammation or persistent disease. Each item represents a disease manifestation and is given a score (of 1) if present for at least 3 months. Neither the cause of damage (vasculitis vs treatment) nor an ongoing activity are taken into consideration. The VDI includes 64 items categorized into 11 groups (by organ system) and the scored items are summed to give a total score ranging from 0 to 64. A higher score means more accrued damage. (NCT02749292)
Timeframe: 3 years starting at inclusion
| Intervention | score on a scale (Mean) | |
|---|---|---|
| VDI at inclusion | VDI at 3 years | |
| B Cell Reconstitution | 1.27 | 1.42 |
| Serologic ANCA Flare | 1.07 | 1.08 |
5 reviews available for prednisolone and ANCA-Associated Vasculitides
| Article | Year |
|---|---|
Factors associated with cytomegalovirus infection in antineutrophil cytoplasmic antibody-associated vasculitis: A narrative review.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytoplasmic; | 2022 |
S2. Rituximab for ANCA-associated vasculitis: the UK experience.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytoplasmic; | 2013 |
[Current status and perspective of vasculitis in Japan].
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-Derived; | 2014 |
[Therapy and prognosis of medium and small vessel vasculitis].
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Cyclophosphamide; Drug Therapy, Combinat | 2014 |
Refractory antineutrophil cytoplasmic antibody-associated vasculitis successfully treated with rituximab: a case report.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytoplasmic; | 2010 |
8 trials available for prednisolone and ANCA-Associated Vasculitides
| Article | Year |
|---|---|
Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Autoantibodies; Cost-Benefit Analysis; C | 2022 |
The HAVEN study-hydroxychloroquine in ANCA vasculitis evaluation-a multicentre, randomised, double-blind, placebo-controlled trial: study protocol and statistical analysis plan.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytoplasmic; | 2023 |
Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; A | 2017 |
Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Dose-Response Relationship, Drug; Drug T | 2017 |
Leg muscle strength is reduced and is associated with physical quality of life in Antineutrophil cytoplasmic antibody-associated vasculitis.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Cross-Sectional Studies; Female; H | 2019 |
Leg muscle strength is reduced and is associated with physical quality of life in Antineutrophil cytoplasmic antibody-associated vasculitis.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Cross-Sectional Studies; Female; H | 2019 |
Leg muscle strength is reduced and is associated with physical quality of life in Antineutrophil cytoplasmic antibody-associated vasculitis.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Cross-Sectional Studies; Female; H | 2019 |
Leg muscle strength is reduced and is associated with physical quality of life in Antineutrophil cytoplasmic antibody-associated vasculitis.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Cross-Sectional Studies; Female; H | 2019 |
Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement.
Topics: Adalimumab; Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Mon | 2010 |
Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytopla | 2012 |
Improvement in health-related quality of life in MPO-ANCA-associated vasculitis patients treated with cyclophosphamide plus prednisolone: an analysis of 18 months of follow-up data from the JMAAV study.
Topics: Aged; Aged, 80 and over; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Asian People; A | 2012 |
47 other studies available for prednisolone and ANCA-Associated Vasculitides
| Article | Year |
|---|---|
Outcome of rituximab treatment in Japanese patients with ANCA-associated vasculitis in daily clinical practice: A two-centre study in Fukushima, Japan.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; East Asian People; Humans; Japan; | 2023 |
Antineutrophil Cytoplasmic Antibody-associated Vasculitis after COVID-19 Vaccination with Pfizer-BioNTech.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytopla | 2022 |
Development of eosinophilic granulomatosis with polyangiitis during the clinical course of microscopic polyangiitis: A case report.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytoplasmic; | 2022 |
Glomerulonephritis associated with systemic sclerosis: a case report.
Topics: Adult; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytopl | 2023 |
Prevalence and risk factors of osteonecrosis of the femoral head in patients with ANCA-associated vasculitis: a multicentre cohort study.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Femur Head; Humans; Osteonecrosis; Predn | 2023 |
Gradual increase of avacopan dose with concomitant ursodeoxycholic acid use may help avoid the risk of C5a receptor inhibitor-induced liver injury in antineutrophil cytoplasmic antibody-associated vasculitis.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytopla | 2023 |
A case of anti-neutrophil cytoplasmic antibody-associated vasculitis with anti-glomerular basement membrane antibodies that was successfully treated with mizoribine as a safe and effective remission maintenance therapy with prednisolone and plasma exchang
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytopla | 2020 |
Long-term outcomes in elderly patients with ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Neutrophil Cytoplasmic Antibody-Associated Vascu | 2020 |
Rationale of concomitant cyclophosphamide for remission-induction in patients with antineutrophil cytoplasmic antibody-associated vasculitis: A propensity score-matched analysis of two nationwide prospective cohort studies.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil | 2021 |
Severe proximal muscle weakness with normal CK as a presenting feature of ANCA-associated vasculitis.
Topics: Aged, 80 and over; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Biopsy; Delayed Diagn | 2020 |
Risk factors for treatment resistance and relapse of Chinese patients with MPO-ANCA-associated vasculitis.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Creatinine; Cyclophosphamide; Fema | 2020 |
ANCA vasculitis and IgA nephropathy linked to silica exposure.
Topics: Acute Kidney Injury; Adult; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, | 2020 |
Development of central retinal artery occlusion accompanied by choroidal folds in a patient with antineutrophil cytoplasmic antibody-associated vasculitis: A case report.
Topics: Aged; Anti-Inflammatory Agents; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Azathiop | 2020 |
Therapeutic dilemmas in relapsing renal ANCA-associated vasculitis.
Topics: Acute Kidney Injury; Aged; Anti-Inflammatory Agents; Anti-Neutrophil Cytoplasmic Antibody-Associated | 2021 |
Refractory ANCA-associated vasculitis.
Topics: Adult; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Glucocorticoids; Humans; Immunolo | 2021 |
Vasculitis: A CLEAR argument for targeting complement in ANCA vasculitis.
Topics: Aniline Compounds; Anti-Inflammatory Agents; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculi | 2017 |
Characteristics and Visual Outcome of Refractory Retinal Vasculitis Associated With Antineutrophil Cytoplasm Antibody-Associated Vasculitides.
Topics: Adult; Age of Onset; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Coloring Agen | 2018 |
Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis (AAV) Restricted to the Limbs.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytoplasmic; | 2018 |
Risk Factors for Relapse of Antineutrophil Cytoplasmic Antibody-associated Vasculitis in Japan: A Nationwide, Prospective Cohort Study.
Topics: Administration, Oral; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Female; Foll | 2018 |
Rituximab-induced Acute Thrombocytopenia in Granulomatosis with Polyangiitis.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Female; Granulomatosis with Polyan | 2018 |
Propylthiouracil-induced Otitis Media with Antineutrophil Cytoplasmic Antibody-associated Vasculitis.
Topics: Adult; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytopl | 2018 |
Unusual case of chronic recurrent multifocal osteomyelitis.
Topics: Adolescent; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil C | 2018 |
Hydralazine-associated antineutrophil cytoplasmic antibody vasculitis with pulmonary-renal syndrome.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Biopsy; Blood Protein Electrophore | 2018 |
Clinical outcome in anti-neutrophil cytoplasmic antibody-associated vasculitis and gene variants of 11β-hydroxysteroid dehydrogenase type 1 and the glucocorticoid receptor.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adult; Aged; Alleles; Anti-Neutrophil Cytoplasmic Antib | 2019 |
Hypertrophic pachymeningitis and cerebral venous thrombosis in myeloperoxidase-ANCA associated vasculitis.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytoplasmic; | 2019 |
Systemic vasculitis associated with anti-neutrophil cytoplasmic antibodies against bactericidal/permeability increasing protein.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytopla | 2013 |
A myelopoiesis gene signature during remission in anti-neutrophil cytoplasm antibody-associated vasculitis does not predict relapses but seems to reflect ongoing prednisolone therapy.
Topics: Aged; Anti-Inflammatory Agents; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodi | 2014 |
Successful treatment of refractory aortitis in antineutrophil cytoplasmic antibody-associated vasculitis using tocilizumab.
Topics: Anti-Inflammatory Agents; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, An | 2014 |
Induction treatment of ANCA-associated vasculitis with a single dose of rituximab.
Topics: Adult; Aged; Aged, 80 and over; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodi | 2014 |
Altered B cell balance, but unaffected B cell capacity to limit monocyte activation in anti-neutrophil cytoplasmic antibody-associated vasculitis in remission.
Topics: Adult; Aged; Aged, 80 and over; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; B-Lympho | 2014 |
[Case of CNS-limited ANCA-associated vasculitis presenting as recurrent ischemic stroke].
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytopla | 2014 |
A rare association between Fabry's disease and granulomatosis with polyangiitis: a potential pathogenic link.
Topics: Adult; alpha-Galactosidase; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, | 2014 |
Experience with seven Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with remission-induction therapy with intravenous cyclophosphamide according to the CYCLOPS protocol.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Anti-Neutrophil Cytoplasmic Antibody-Associate | 2014 |
Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.
Topics: Adult; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-De | 2015 |
Intravascular Large B-Cell Lymphoma Complicated by Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis that was Successfully Treated with Rituximab-Containing Chemotherapy.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-Derived; | 2015 |
A Case of ANCA-associated Large Vessel Vasculitis with Multiple Saccular Aneurysms.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytopla | 2016 |
Unusual cause of flare in antineutrophil cytoplasmic antibody-associated vasculitis.
Topics: Absorption, Physicochemical; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, | 2016 |
Brief Report: Menopause and Primary Ovarian Insufficiency in Women Treated for Antineutrophil Cytoplasmic Antibody-Associated Vasculitides.
Topics: Adult; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Azathioprine; Case-Control Studie | 2016 |
Pulmonary Nocardiosis Caused by Nocardia concava with a Literature Review.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Humans; Immunocompromised Host; Im | 2016 |
Antineutrophilic cytoplasmic antibody-associated vasculitis with hypocomplementemia has a higher incidence of serious organ damage and a poor prognosis.
Topics: Aged; Anti-Inflammatory Agents; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Compleme | 2016 |
Mizoribine reduces serum KL-6 levels in ANCA-associated vasculitis.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Biomarkers; Female; Humans; Mucin- | 2010 |
Vasculitis syndromes: Inducing remission in ANCA-positive vasculitis: time to RAVE?
Topics: Administration, Oral; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monocl | 2010 |
[Case of MPO-ANCA-associated vasculitis with membranous nephropathy].
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Female; Glomerulonephritis, Membra | 2011 |
Rituximab associated pneumonitis in antineutrophil cytoplasmic antibody-associated vasculitis.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-Der | 2012 |
ANCA-associated systemic vasculitis in Japan: clinical features and prognostic changes.
Topics: Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Cohort Studies; Creatinine; Cyclop | 2012 |
ANCA-associated vasculitis with dual ANCA positivity in coexistence with mixed connective tissue disease.
Topics: Adult; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytopl | 2013 |
Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
Topics: Adolescent; Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Ant | 2012 |